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Abstract: Recent studies have identified sex-differences in auditory physiology and in the susceptibility to noise-induced hearing loss (NIHL). We hypothesize that 17β-estradiol (E2 ), a known modulator
of auditory physiology, may underpin sex-differences in the response to noise trauma. Here, we
gonadectomized B6CBAF1/J mice and used a combination of electrophysiological and histological
techniques to study the effects of estrogen replacement on peripheral auditory physiology in the
absence of noise exposure and on protection from NIHL. Functional analysis of auditory physiology
in gonadectomized female mice revealed that E2 -treatment modulated the peripheral response to
sound in the absence of changes to the endocochlear potential compared to vehicle-treatment. E2 replacement in gonadectomized female mice protected against hearing loss following permanent
threshold shift (PTS)- and temporary threshold shift (TTS)-inducing noise exposures. Histological
analysis of the cochlear tissue revealed that E2 -replacement mitigated outer hair cell loss and cochlear
synaptopathy following noise exposure compared to vehicle-treatment. Lastly, using fluorescent in
situ hybridization, we demonstrate co-localization of estrogen receptor-2 with type-1C, high threshold spiral ganglion neurons, suggesting that the observed protection from cochlear synaptopathy
may occur through E2 -mediated preservation of these neurons. Taken together, these data indicate
the estrogen signaling pathways may be harnessed for the prevention and treatment of NIHL.
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1. Introduction
Disabling hearing loss afflicts nearly half a billion people worldwide. Noise-induced
hearing loss (NIHL)—a form of acquired hearing loss—comprises a significant portion of
this global burden, and its incidence is expected to increase [1,2]. Despite its widespread
prevalence, there are currently no FDA-approved therapeutics for the prevention or treatment of NIHL, leaving amplification (hearing aids) and cochlear implantation as the sole
treatment options [3,4].
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The severity of NIHL presents as a continuum. Small increases in the intensity or
duration of a noise exposure result in the progression from a less severe to a more severe
subtype [5]. The least severe subtype of NIHL—referred to as a temporary threshold
shift (TTS)—results in a temporary elevation of auditory thresholds without loss of, or
permanent damage to, the mechanosensory cells of the cochlea—inner hair cells (IHCs)
and outer hair cells (OHCs)—or their associated auditory nerve fibers (ANFs) arising
from the spiral ganglion neurons (SGNs) [6]. A more severe subtype of NIHL called
cochlear synaptopathy also produces a TTS but causes uncoupling and/or dysfunction of
the synaptic connections between IHCs and high-threshold, low-spontaneous rate SGNs,
which appear to correspond to type-1C SGNs [7–10]. In humans, cochlear synaptopathy is
believed to underpin ‘hidden hearing loss’ (HHL), a functional impairment that includes
difficulty understanding speech in noise [9,11]. Finally, the most severe subtype of NIHL
results in a permanent elevation of auditory thresholds—or permanent threshold shift
(PTS)—with attendant damage to, or loss of, IHCs and OHCs. Following octave-band
noise exposures, this loss often occurs half an octave above the noise band and in the
more vulnerable basal portions of the cochlea, where basal OHCs display an intrinsic
vulnerability to damage caused by free radicals compared to more apical OHCs [6,12–14]
While NIHL afflicts both males and females, recent evidence suggests that females
display increased resilience to NIHL compared to males, and that this resilience may be
mediated by estrogen signaling [15–21]. Recent findings from our laboratory demonstrate
that gonadally intact female mice are relatively protected from a PTS-inducing noise
exposure in comparison to gonadally intact males [16]. Furthermore, estrogen receptor-β
(estrogen receptor 2 or ESR2) knockout (KO) mice of both sexes are more susceptible to
TTS-inducing noise exposures than their wildtype littermate controls, while female ESR2
KO mice display early onset age-related hearing loss (ARHL) [22,23]. Both findings suggest
that this protective effect may be, at least in part, mediated via ESR2-signaling.
The apparent protective effects of the estrogen signaling pathways offer a compelling
avenue of investigation into their therapeutic potential. In the present study, we utilize a
surgical gonadectomy model to characterize the effects of estrogen removal and replacement on peripheral auditory physiology in the absence of noise exposure. The surgical
gonadectomy model eliminates circulating gonadal steroids including endogenous E2 in
mice of both sexes, as E2 is generated in males by the aromatization of testosterone [24]. This
model allows for control of circulating estrogen levels in vivo, and is a well-established
model for the study of estrogenic modulation [25,26]. Next, using the same gonadectomy model, we characterize the effects of estrogen replacement in the context of either
a PTS-inducing noise exposure (102.5 dB sound pressure level [SPL], 8–16 kHz, 2-h) or a
less-severe, TTS-inducing noise exposure that causes cochlear synaptopathy (94 dB SPL,
8–16 kHz, 2-h).
Our data indicate that estrogen replacement modulates peripheral auditory physiology in female mice in the absence of noise exposure. We also demonstrate that estrogen
replacement in gonadectomized female mice reduces auditory threshold shifts following
both a PTS-inducing and TTS-inducing noise exposure. Furthermore, we show that surgical
gonadectomy increases, and estrogen replacement decreases, OHC loss and cochlear synaptopathy. Finally, using fluorescent in situ hybridization, we demonstrate colocalization of
Esr2 with type-1C SGNS, suggestive of an E2 -mediated protective effect against cochlear
synaptopathy through preservation of type-1C SGNs. Taken together, these data indicate
the estrogen signaling pathways may show promise for the prevention and treatment
of NIHL.
2. Results
2.1. E2 -Replacement Decreases Auditory Thresholds and Increases Wave-1 Amplitude
We quantified auditory brainstem responses (ABRs), which reflect synchronous neural
activity along the ascending auditory pathway [27], to evaluate the effects of E2 -replacement
on peripheral auditory physiology in the absence of noise exposure. Eight-week-old
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We observed no changes in DPOAE thresholds in mice that received vehicle injections during both weeks of data collection (Figure 2C). In contrast, in the cohort that
received E2 -replacement during the second week of data collection, within-group analysis
revealed improved DPOAE thresholds following E2 -replacement at 10 kHz (p = 0.0216)
and 28 kHz (p = 0.0001), suggesting that E2 -replacement modulates OHC physiology in
gonadectomized female mice in the absence of noise exposure (Figure 2D).
2.3. E2 -Replacementon Does Not Affect the Endocochlear Potential
Another possible explanation for the observed electrophysiological changes, including
the improvement in DPOAE thresholds, is that E2 -replacement modulates the endocochlear
potential (EP). The apical surfaces of the mechanosensory cells in the inner ear are bathed
in an extracellular fluid called endolymph, normally characterized by a high potassium
(K+ ) concentration and a positive electric potential (in mice) of about 100 mV [31,32]. This
positive EP is critical for cochlear hair cell mechanotransduction, and changes to the EP
can alter ABR thresholds [33–35]. The EP was measured in 10-week-old vehicle-treated
and E2 -treated female mice (Figure 2A). This experiment was performed two ways in
different cohorts, first using a round window approach (Figure 2E) and second using a
lateral wall approach (Figure 2F) to verify consistency in EP measurements between the
two experimental techniques. We observed no differences between the vehicle-treated and
E2 -treated animals using either experimental approach, indicating E2 -replacement does not
affect the EP, and that the observed electrophysiological changes following E2 -replacement
are not the result of changes to the EP.
2.4. Gonadectomy Eliminates Sex Differences in the Response to PTS-Inducing Noise
Following the evaluation of the effects of E2 -replacement on peripheral auditory
physiology in the absence of noise exposure, we next evaluated the potential protective
effects of E2 -replacement against NIHL. In a previous report, we demonstrated that gonadally intact female B6CBAF1/J mice displayed relative protection from PTS-inducing
noise (101 dB SPL, 8–16 kHz, 2-h) in comparison to gonadally intact males [16]. Here,
we examined whether the previously documented protection from PTS-inducing noise in
female mice is a result of gonadal E2 . Eight-week-old male and female B6CBAF1/J mice
were gonadectomized and implanted with a subcutaneous osmotic pump delivering either
E2 or a vehicle control (Figure 3A). ABR measurements were used to compare hearing
thresholds at 3 timepoints: (1) following gonadectomy and 1-week before noise exposure
(baseline); (2) 24-h post-exposure to quantify the compound threshold shift (CTS) [36]; and
(3) 2-weeks post-exposure to quantify the PTS (Figure 3A).
At baseline, there were no differences in auditory thresholds between vehicle-treated
males and females at any frequency tested (Figure 3B). Twenty-four hours after the PTSinducing exposure, gonadectomized vehicle-treated male and female mice displayed no
differences in the magnitude of the CTS across all frequencies tested (Figure 3C). Similarly,
ABR measurements collected 2-weeks post-exposure in gonadectomized vehicle-treated
male and female mice displayed no differences in the magnitude of the PTS across all
frequencies tested (Figure 3D). These results demonstrate that the sex-dependent protective
effect previously reported is abolished in the absence of circulating gonadal steroids.
2.5. E2 -Replacement Protects against PTS-Inducing Noise in Female Mice
Using the same experimental timeline, in another cohort of mice we then investigated
whether E2 -replacement re-establishes the sex-dependent protective effect [16]. At baseline,
E2 -treated males and females displayed similar ABR thresholds at all frequencies tested.
Additionally, there were no differences in baseline thresholds after E2 -treatment in male or
female mice (Figure 3B).
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2.6. E2 -Replacement Reduces OHC Loss following a PTS-Inducing Noise Exposure
To validate our physiologic data and to obtain tissue for histological analyses, we
utilized an additional cohort where E2 -replacement was administered using subcutaneous
injections of 17β-estradiol-3-benzoate (from here on referred to as E2 ) (Figure 4A). This
cohort used female mice only because we observed E2 -mediated protection from PTSinducing noise exposure in female but not male mice. Cochleae were collected 1-week
following the PTS-inducing noise exposure, since we determined in previous studies that
permanent threshold shifts did not change between the 1-week and 2-week post-exposure
ABRs [16]. In the areas corresponding to the frequency-specific PTS—16 kHz, 24 kHz, and
32 kHz—there was no OHC loss and therefore no difference in OHC survival between
the experimental conditions. However, in the basal portion of the cochlea corresponding
to frequencies between 45.2 kHz and 55.0 kHz, E2 -treated mice displayed significantly
improved OHC survival (p < 0.0001), consistent with an E2 -induced otoprotective effect
(Figure 4B). The pattern of OHC loss following this noise exposure paradigm is consistent
with our previously published data, showing that a similar noise exposure in this strain
of mice results in an extensive loss of OHCs in the basal part of the cochlea, whereas
the frequency-specific hearing loss is associated with OHC dysfunction but not with an
immediate OHC loss [16]. Paired IHC synapses were also quantified from the same
cohort of animals 1-week post-exposure. There were no observed differences in paired
synapse numbers between the E2 -treated and vehicle-treated female mice at any frequency
examined (Figure 4C).
2.7. Protective Effect of E2 -Replacement on Hearing Thresholds following TTS-Inducing Noise
While E2 -replacement ameliorated hearing loss and improved OHC survival in female
mice following a PTS-inducing noise exposure, vehicle-treated and E2 -treated female
mice displayed a similar degree of synapse loss (compare Figures 2B and 4C). The sound
energy required to induce a PTS exceeds the sound energy required to induce cochlear
synaptopathy in CBA/CaJ mice [37], and permanent shifts in auditory thresholds are
concomitant with synaptic uncoupling and dysfunction to a degree that may have exceeded
the therapeutic capacity of E2 -replacement. Thus, to evaluate the effect of E2 -replacement
on protection from cochlear synaptopathy, we utilized a less-intense, TTS-inducing noise
exposure (94 dB SPL, 8–16 kHz, 2-h). Given that the protective effect of E2 was confined to
female mice in the PTS-inducing experiments, our investigation of E2 ’s protective effects
from here on utilized female mice only.
Eight-week-old female B6CBAF1/J mice underwent surgical gonadectomy and subsequently received vehicle treatment or E2 -replacement (Figure 5A). At baseline, there
were no differences in auditory thresholds between the vehicle-treated and E2 -treated mice
(Figure 5B). Twenty-four hours following the noise exposure, analysis of the CTS revealed
that E2 -treated mice displayed a significantly reduced CTS at 16 kHz (p = 0.0266), 24 kHz
(p = 0.0001), and 32 kHz (p = 0.0001), compared to the vehicle-treated mice (Figure 5C).
Consistent with this noise exposure producing a TTS, auditory thresholds returned to
baseline in both experimental conditions, and comparison of the 1-week threshold shifts
between treatment groups revealed no differences (Figure 5D).
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were no differences in auditory thresholds between the vehicle-treated and E2-treated
mice (Figure 5B). Twenty-four hours following the noise exposure, analysis of the CTS
revealed that E2-treated mice displayed a significantly reduced CTS at 16 kHz (p = 0.0266),
24 kHz (p = 0.0001), and 32 kHz (p = 0.0001), compared to the vehicle-treated mice (Figure
5C). Consistent with this noise exposure producing a TTS, auditory thresholds returned
9 of 26
to baseline in both experimental conditions, and comparison of the 1-week threshold shifts
between treatment groups revealed no differences (Figure 5D).
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amplitudes overall compared to vehicle-treated mice (Figure 6A–D, Table 1). One-week
post-exposure, wave-1 amplitudes decreased in both groups of mice but remained larger
overall in the E2 -treated mice, as a comparison of wave-1 amplitudes revealed a significant
main effect of treatment at all frequencies tested (Figure 6A–D). The maintenance of larger
wave-1 amplitudes in the E2 -treated mice suggests increased synchronous neural activity
at the level of the spiral ganglion and potentially an E2 -mediated protection from cochlear
synaptopathy. We therefore quantified the number of paired synapses in vehicle-treated
and E2 -treated mice 1-week post-exposure. Compared to a group of sham exposed mice,
E2 -treated mice displayed the same number of synapses at each frequency examined. In
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One-week post-exposure, wave-1 amplitudes decreased in both groups of mice but remained larger overall in the E2-treated mice, as a comparison of wave-1 amplitudes revealed a significant main effect of treatment at all frequencies tested (Figure 6A–D). The
maintenance of larger wave-1 amplitudes in the E2-treated mice suggests increased synchronous neural activity at the level of the spiral ganglion and potentially an E2-mediated
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2.8. Gonadectomy Increases Susceptibility to OHC Loss
Outer hair cell loss is typically not a pathophysiological outcome of exposure to
TTS-inducing noise [12,38,39]. However, the effect of TTS-inducing noise on OHC
survival has not been previously compared between intact and gonadectomized mice.
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We therefore performed cytocochleograms to examine OHC survival in the same cohort
of animals 1-week post-exposure. As expected, E2 -treated mice did not display any loss
of OHC. In contrast, compared to E2 -treated mice, vehicle-treated mice displayed a 3.9%
increase in OHC loss (p < 0.0001) 1-week post-exposure that was restricted to frequencies
between 16.0 kHz and 22.6 kHz (Figure 7E–H). Like the E2 -treated mice, vehicle-treated
mice did not display significant OHC loss below 16.0 kHz or above 22.6 kHz.
2.9. Canonical Estrogen Receptor Localization
To identify possible mechanisms through which estrogen alters auditory physiology and confers protection against NIHL, we characterized the expression of estrogen
receptors 1 and 2 (Esr1, Esr2) transcripts in male and female mice. Fluorescent in situ
hybridization RNAscope™ assays were performed to localize the receptor transcripts
to specific cell types in the cochlea, with representative images taken from the middle
turn of the cochlea (Figure 8A–F). No sex differences in the localization of either Esr1
or Esr2 were detected. In the organ of Corti, expression of Esr1 and Esr2 was observed
at low levels in the IHCs, whereas the OHCs demonstrated no expression of either
receptor (Figure 8A,D). Moderate levels of Esr1 and Esr2 expression were seen within
the stria vascularis (SV), with Esr1 similarly distributed throughout the three cell layers
comprising the SV (Figure 8B,E). Distribution of Esr2 mRNA appeared more highly
expressed in the basal cell layer compared to the marginal and intermediate cells. In
contrast to the organ of Corti and stria vascularis, the most abundant expression of
estrogen receptors was observed within the SGNs (Figure 8C,F). Interestingly, while
Esr1 expression was lower and diffuse throughout the SGNs, Esr2 exhibited robust and
highly specific expression in a subset of neurons.
To determine the identity of this SGN subtype, additional fluorescent in situ hybridization assays were performed using a probe for Lypd1, an type-1C SGN marker, in
combination with a probe for Esr2 [10]. In both male and female mice, we found significantly greater co-expression of Lypd1 and Esr2 together versus Esr2 alone (p < 0.0001),
suggesting Esr2 localization is primarily confined to the type-1C SGNs in the adult mouse
cochlea (Figure 8G–I).
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In the absence of endogenous gonadal hormones, we demonstrated that males and females are equally susceptible to noise exposure. Our data show that E2-replacement in
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E2 -replacement increased OHC survival in female mice following both types of noise
exposures. To our surprise, surgical gonadectomy without E2 -replacement resulted in
a focal loss of OHCs between 16.0 kHz and 22.6 kHz 1-week following a TTS-inducing
noise exposure. Frequency-specific OHC loss has not generally been reported for any
animal model following a TTS-inducing exposure [12,38,39], nor was frequency-specific
OHC loss observed in intact female mice of the same strain (B6CBAF1/J) following a more
intense PTS-inducing noise exposure [16]. These results suggest that OHCs in females
are uniquely vulnerable to noise exposure in the absence of baseline levels of circulating
gonadal steroid hormones and are prone to cell death even following less-intense noise
exposures. The potential translational significance of this finding for post-menopausal
women is supported by additional evidence demonstrating that the decrease in E2 levels
associated with menopause prompts a decline in hearing sensitivity [40,41].
In mice exposed to TTS-inducing noise, E2 -replacement prevented cochlear synaptopathy at 24 kHz, the frequency with the maximal CTS in our animal model. The observed
protection from synaptopathy may occur via prevention of the uncoupling of the paired
IHC-ANF synapses, synaptic regeneration, or a combination of both phenomena. Recent
studies demonstrate the potential for synaptic regeneration as treatment with bisphosphonates 24-h post-exposure can reverse synaptopathy [42]. Histological evaluation at additional post-exposure timepoints is needed to discriminate the two proposed mechanisms.
Our data also demonstrate that E2 -replacment is sufficient to modulate peripheral
auditory physiology in the absence of noise exposure. In particular, we observed a robust
effect of E2 -replacement on wave-1 amplitude, where E2 -treated female mice displayed
larger wave-1 amplitudes at all frequencies examined despite no differences in the number
of paired IHC-ANF synapses. An increase in wave-1 amplitudes in the absence of changes
to paired synapse numbers could arise from the non-genomic actions of estrogens, which
include the regulation of calcium signaling and cyclic adenosine monophosphate (cAMP).
Previous studies demonstrate that estrogens potentiate L-type calcium channels like CaV1.3,
which is found at the inner hair cell synapse [43,44]. An increase in cAMP and CaV1.3
conductance could lead to an increase in glutamate release [45]. The increase in glutamate
release, in turn, could lead to an increase in the speed, or number, of spike generations
and cause an increase in wave-1 amplitude [46]. Further functional studies are required to
investigate this hypothetical mechanism.
E2 is a known ligand of the two classical estrogen receptors, ESR1 and ESR2. Upon
binding with E2 , ESR1 and ESR2 homo- and hetero-dimerize and translocate to the nucleus
where they regulate transcription of target genes [19,47]. Previous reports suggest that ESR1
and ESR2 are both expressed in the cochlea of CBA inbred strains [48,49] and that protein
levels of ESR2 may be expressed at a higher level than ESR1 in the inner ear SGNs [48].
Furthermore, ESR2 has been functionally implicated in ARHL and NIHL [22,23]. Our
data demonstrate localization of both Esr1 and Esr2 transcripts in the SGNs of intact
adult male and female mice. However, we also show that Esr2 localizes more specifically
to type-1C SGNs. These data provide additional evidence to support our hypothesis
that the protective effects of estrogen-signaling following noise exposure—in this case, the
amelioration of cochlear synaptopathy following noise trauma—may be mediated via ESR2.
Previous studies have suggested that synaptopathy-inducing noise results specifically in
the retraction of type-1C fibers, suggesting E2 -replacement protects against the loss of
type-1C SGNs that characterizes synaptopathy [9,10]. In support of the histologic data that
suggest SGNs are responsive to E2 -treatment, we show that unexposed E2 -treated female
mice display increased ABR wave-1 amplitudes at all frequencies tested. Future studies
should ask why type-IC SGNs may be protected in the presence of E2 .
In contrast to the robust expression detected in the SGNs, we detected no expression of
Esr1 or Esr2 transcripts in the OHCs. A previous report demonstrated faint immunostaining
of ESR1 and negative immunostaining of ESR2 in the OHCs of CBA mice [49]. Nevertheless,
E2 -treated mice displayed improved DPOAE thresholds—a proxy for OHC function—in
the absence of changes to the endocochlear potential. These data suggest that the effect of
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E2 on OHC physiology is not likely to be mediated via the canonical estrogen receptors
ESR1 or ESR2 and may be modulated via another estrogen receptor such as GPER1,
the estrogen-related receptors (ESRRα, ESRRβ, and ESRRγ), through a more complex
interaction between the classical and related receptors [50], or through increased activation
of the projections of the medial olivocochlear bundle [51].
We report, for the first time, an E2 -mediated protection against cochlear synaptopathy
following noise exposure. The literature provides examples of E2 -mediated regulation of
synaptic plasticity elsewhere [52–54]. In the central nervous system (CNS), E2 -signaling—
particularly through the classical estrogen receptor ESR2—has been shown to enhance
synaptic plasticity through an increase in expression of TRKB and BDNF [55]. In the
cochlea, TRKB and BDNF have been shown to prevent neuronal retraction following noise
exposure—the currently known pathophysiology to underpin cochlear synaptopathy [56,57].
The role of gonadal E2 as a neuroprotectant and neuromodulator is also well-established [58,59].
Ovariectomy of female mice induced an increase in amyloid beta plaques in a model of
Alzheimer’s disease, while E2 -replacement partially ameliorated this effect [60]. Additional studies demonstrated that surgical ovariectomy without E2 -replacement increases
vulnerability of hippocampal neurons in a model of glutamatergic excitotoxicity, and that
prophylactic E2 -replacement prevented this vulnerability [61]. Of significance, glutamatergic
excitotoxicity is thought to be a key mediator of noise-induced cochlear synaptopathy [62–64].
Taken together, our data show an E2 -mediated otoprotective effect from noise-induced
synaptopathy that is consistent with the role of E2 -signaling in the CNS and likely mediated via ESR2. These findings are clinically significant, as ESR2-mediated signaling is
non-feminizing, and FDA-approved ESR2-modulators are already available [65,66].
Our data further indicate that the otoprotective effects of gonadal E2 against PTSinducing noise exposure may be confined to females, and that females and males are equally
susceptible to PTS-inducing noise when devoid of their gonadal hormones. Additional
investigation is needed to determine whether E2 is protective against TTS-inducing noise in
male mice. Consistent with our findings, in a model of Parkinson’s disease, E2 -replacement
in gonadectomized female rats conferred neuroprotection, while E2 -replacement in gonadectomized males proved deleterious [67]. Conversely, in other models, E2 -replacement
has shown beneficial effects in gonadectomized rats of both sexes. E2 -replacement has
shown to suppress the increase in brain mitochondrial oxidative stress following gonadectomy [68] and confer neuroprotection in an experimental model of stoke [69,70]. Taken
together, these reports indicate a tissue-specific interaction between biological sex and the
neuroprotective effects of gonadal E2 .
The system-specific similarities and differences in the neuroprotective actions of E2
in males and females are likely due to a combination of organizational and activational
effects. Organizational effects arise from changes during the developmental hard wiring
of the brain, whereas activational effects arise from modulation by circulating gonadal
hormones [59,71]. In support of an organizational component, both male and female ESR2
KO mice show increased susceptibility to TTS-inducing noise [22]. Additional evidence
for an organizational component in the auditory system arise from studies of ESRRα,
ESRRβ, and ESRRγ. These receptors do not bind E2 , but nevertheless regulate many of
the same transcriptional targets as ESR1 and ESR2 [50]. At least one identified human
polymorphism in ESRRβ predicts audiometric TTS in musicians of both sexes, while
additional polymorphisms in ESRRβ and ESRRγ cause non-syndromic, congenital hearing
impairment and are also implicated in the maintenance of hearing [72–75]. On the other
hand, our data suggest E2 also influences susceptibility to/protection from NIHL via
activational effects. Elimination of gonadal steroid hormones via surgical gonadectomy
abolishes—and E2 -replacement re-establishes—an innate relative protection from PTSinducing noise in adult female mice in comparison to males. Additional evidence in
humans demonstrating changes in hearing sensitivity and DPOAE amplitudes in preand post-menopausal women also implicate activational effects of E2 -signaling in the
modulation of auditory physiology [76,77].
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The findings presented here are immediately clinically relevant, not only for the treatment of NIHL, but also for the treatment of other diseases of the auditory and vestibular
system, such as Meniere’s Disease, in which E2 levels can correlate with symptom severity [77]. The characterization of sex-differences in NIHL and ARHL—which share common
mechanisms [78,79]—figures to bear heavily on the development of new therapeutics. In
fact, previous reports already suggest that experimental NIHL therapeutics may exhibit
sex-dependent efficacy [16,17]. Furthermore, existing FDA-approved, tissue-specific ESR2
modulators, like raloxifene (currently approved for treatment of osteoporosis in postmenopausal women), have been shown to confer neuroprotective effects in a mouse model
of epilepsy [80], rendering such drugs as potential candidates for protection of hearing.
4. Materials and Methods
4.1. Animals
All animals utilized in the experiments were B6CBAF1/J mice (Jackson Laboratory,
Bar Harbor, ME, USA; Stock No 100011). These mice are F1 progeny from a cross between
C57BL/6J and CBA/J, which eliminates the influence of strain-specific recessively inherited
traits such as resistance or susceptibility to ARHL, NIHL, or sound-induced seizures [16].
The animal facility is controlled for temperature and humidity and has a 12-h light/dark
cycle (lights on at 7 a.m.). Mice were provided with dry food and water ad libitum. All
surgical and experimental procedures took place during the animals’ light phase. Animals
were euthanized by CO2 asphyxiation or terminal perfusion with 4% paraformaldehyde
and then decapitated.
DPOAE testing and lateral wall EP measurement were completed at the Washington
University School of Medicine in St. Louis using a separate cohort of animals. Round
window EP measurements were completed at the National Institute on Deafness and
other Communication Disorders using a separate cohort of animals. All other animal
experiments were completed at the University of Maryland School of Medicine. No
animals were transported between institutions at any time.
4.2. Gonadectomy
Mice were gonadectomized at 8-weeks of age. Anesthesia was achieved with isoflurane gas. In the female mice, bilateral ovariectomy was performed by making a 5 mm,
longitudinal, dorsal incision through the skin and muscle wall. The ovary was separated
from the uterus lateral to the oviduct using electrocautery, and the uterine horn was repositioned in the abdominal cavity. The muscle wall was closed using a 4–0 poliglecaprone
suture (MWI Animal Health, Boise, ID, USA), and the skin was closed using a 4–0 nylon suture (MWI Animal Health, ID). The same procedure was then repeated on the contralateral
ovary. In the male mice, bilateral gonadectomy was performed by making a single 2–3 mm,
longitudinal, ventral incision through the scrotum. The testes were separated from the seminal vesicles with electrocautery. The skin was closed as described above. Incision sites were
treated with a 2.5% lidocaine and 2.5% Prilocaine Cream (Akorn, Lake Forest, IL, USA) and
Bacitracin Zinc antibiotic ointment (Trifecta Pharmaceuticals, Fort Lauderdale, FL, USA).
Carprofen (0.05 mg/kg) was administered by subcutaneous injection immediately before
the surgical procedure and 24-h post-operatively for analgesia.
4.3. Subcutaneous Pump Placement
Eight-week-old male and female mice underwent surgical gonadectomy as described
above. During the procedure, animals were implanted with the Alzet 1004® micro-osmotic
pump (DURECT Corporation, Cupertino, CA, USA). In female mice, pumps were implanted subcutaneously via the incision created during the ovariectomy. In male mice, a
1 cm, dorsal, longitudinal incision was made between the scapulae. To offset the position of
the pump relative to the incision, a subcutaneous pocket was developed by blunt dissection
lateral to the incision. All animals recovered for 5–7 days prior to the baseline ABR.
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4.4. Hormonal Treatments
We utilized three hormonal regimens to generate the data presented in this manuscript.
In our experiments evaluating the acute effects of hormone replacement on auditory
physiology in the absence of noise exposure, we utilized a series of daily subcutaneous
injections administered over a period of 3–4 days. Mice in the NIHL experiments received
continuous hormonal replacement for the duration of the studies, a period of 3–4 weeks,
which was achieved using either implanted subcutaneous pumps or serial subcutaneous
injections. Pumps were utilized in the initial NIHL experiments. Subsequent experiments
utilized serial subcutaneous injections, which provided greater control and increased
confidence in successful hormone delivery.
4.4.1. Acute Hormonal Supplementation Using Subcutaneous Injections
Mice were administered daily subcutaneous injections of E2 (Sigma-Aldrich, St. Louis,
MO, USA) (300 µg/kg) reconstituted in sesame oil (vehicle) (Sigma-Aldrich)—or vehicle
only—for a period of 3–4 days. This dose was chosen to acutely elevate serum E2 to supraphysiologic levels prior to electrophysiological evaluation of baseline auditory function.
4.4.2. Continuous Hormonal Supplementation Using Osmotic Pumps
The Alzet® 1004 micro-osmotic pump was loaded with either 17β-estradiol (E2 )
(Sigma-Aldrich) at a concentration of 38 µg/100 µL in propylene glycol (PPG) or PPG only.
The pump delivered 0.11 µL/h of the loaded solutions at a steady release rate to administer
a dose of 1 µg of E2 /day. Drug administration began immediately after pump implantation
and continued the entire duration of the study. Serum E2 delivery was confirmed qualitatively and quantitatively at the conclusion of the study, four weeks after implantation
(Figure A1). Following euthanasia via CO2 asphyxiation, the female uterine horns and
the male seminal vesicles were exposed and photographed for comparison (Figure A1).
Trunk blood was collected, and the sera were processed for estradiol levels as measured via
ELISA (ES180S-100, CalBiotech, El Cajon, CA, USA) performed at University of Virginia
Ligand Assay and Analysis Core) (Figure A1).
4.4.3. Continuous Hormonal Supplementation Using Subcutaneous Injections
Two to 3 days following surgical gonadectomy, mice were administered subcutaneous
injections of 17β-estradiol-3-benzoate (EB) (Sigma-Aldrich) at a concentration of 150 µg/kg
reconstituted in sesame oil (vehicle) (Sigma-Aldrich)—or the vehicle only—every other day
for the duration of the study. EB is a synthetic pro-drug ester of 17β-estradiol that is deesterified by nonspecific steroidal esterases to produce biologically active E2 in vivo [81,82].
EB delivery is a commonly used method of E2 replacement that permits administration of
subcutaneous injections every other day rather than every day due to its longer half-life
relative to E2 . Mice that received E2 -replacement via injections of EB will, from hereon, be
described as E2 -treated or as having received E2 -replacement following euthanasia, the
female uterine horns were exposed and photographed for comparison to confirm successful
E2 replacement (Figure A1).
4.5. Noise Exposures
Noise exposures were performed using the methods previously described [16]. All
mice underwent calibrated noise exposure at 10-weeks of age at the same time of day
(8:00 am). Octave-band noise centered at 11.3 kHz (8–16 kHz) was delivered for 2-h using the Fostex FT17H tweeter (Fostex, Tokyo, Japan). Noise was delivered at 102.5 dB
sound pressure level (SPL) to induce a PTS or at 94 dB SPL to induce a TTS with cochlear
synaptopathy. Calibration was achieved with a measurement microphone (PCB Piezotronics, Depew, NY, USA) placed at the same distance from the tweeter as the mouse’s ears.
The tweeter was placed 20 cm above the mice and the sound level was measured to
be within 0.5 dB of the target level. During the exposure, mice were placed in a custom holder constructed of perforated aluminum sheets (18 × 15 × 5 cm) with eight
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equal sized chambers (4.5 × 7.5 × 5 cm) in an acoustically controlled box (IAC Acoustics,
North Aurora, IL, USA). Only the four central compartments were used to expose a maximum of four mice simultaneously. The animals were awake and unrestrained throughout
the exposure.
4.6. Auditory Brainstem Response (ABR)
ABRs were performed using methods described previously [16]. ABRs were recorded
at baseline (5–7 days pre-exposure), 24-h after the noise exposure to quantify the compound threshold shift (CTS), and 1–2 weeks after the noise exposure to quantify the
permanent threshold shift (PTS) or to confirm a temporary threshold shift (TTS). Animals
were anesthetized using an intraperitoneal injection of ketamine (100 mg/kg) (Vet One,
Boise, ID, USA) and xylazine (20 mg/kg) (Akorn, Lake Forest, IL, USA). Using the RZ6
recording system (Tucker-Davis Technologies (TDT), Alachua, FL, USA), hearing thresholds were determined at 8 kHz, 16 kHz, 24 kHz, and 32 kHz in an acoustically controlled
box (IAC Acoustics, IL). Once surgical levels of anesthesia were achieved, animals were
positioned so that they directly faced the tweeter with their ears 10 cm from the front of
the tweeter. Subcutaneous electrodes were placed at the post-auricular area of the left and
right ears, and at the vertex of the skull for the reference. The ground electrode was placed
at the base of the tail. Output stimuli were calibrated with a measurement microphone
(PCB Piezotronics, NY) placed at the same distance from the tweeter as the mouse’s ears
(10 cm). Frequency-specific tone bursts 2.5 milliseconds (ms) long, with a 0.5 ms sinusoidal
on- and off-ramp were delivered with alternating polarity beginning at 90 dB SPL. Tone
bursts were progressively decreased by 5 dB until 10 dB below the measurable hearing
threshold for each mouse. Electrophysiologic responses to each tone stimulus, filtered
between 300 Hz and 3000 Hz, were recorded for 10 ms starting at the onset of the tone,
with a total of 512 sweeps at a rate of 21 sweeps/second, and then averaged at each sound
level and frequency tested. The responses from each ear were recorded simultaneously.
The hearing threshold was defined as the lowest level at which either ABR waves 1 or 2
could be identified. Thresholds were averaged between the two ears and reported as a
single value per animal.
Suprathreshold wave-1 amplitudes were extracted offline according to methods described previously [16]. Peak-to-trough wave-1 amplitude was calculated using the maximum positive deflection after 1 ms in the recording and the subsequent maximum negative
deflection. Wave-1 amplitudes were averaged between the two ears and reported as a
single value per animal.
4.7. Distortion Product Otoacoustic Emissions (DPOAE)
DPOAE data (2f1–f2) were collected at the Washington University School of Medicine
in St Louis. All recordings were from the left ear. Animals were anesthetized using
ketamine and xylazine (80/15 mg/kg, intraperitoneally) and positioned dorsally in a
custom headholder. Body temperature was monitored throughout testing using a rectal
probe and maintained at 37.5 ± 1.0 ◦ C using a DC current-based isothermal pad (Frederick
Haer, Bowdoin, ME, USA). DPOAE input/output relations were obtained for f2’s of 10,
20, and 28.3 kHz using Otoacoustic Emission Average (EMAV) (Boys Town National
Research Hospital, Boys Town, NE, USA) in conjunction with TDT and custom hardware.
f1 frequencies were given by f2/1.2. The level of f1 (L1) varied from 10 to 90 dB SPL in 5 dB
steps while the level of f2 (L2) varied as L1–10 dB. Stimuli were delivered to the ear using a
custom coupler inserted using an operating scope. Each channel was output to a TDT EC-1
speaker. DPOAE responses were recorded using a Knowles FC-23652-P16 microphone
calibrated to 40 kHz and digitized at 192 kHz. DPOAE thresholds were defined as the
minimum sound level required to produce a response of at least −5 dB SPL, well above
typical noise levels of about −20 dB SPL. When sound levels straddled this response size,
the threshold was taken to be the midpoint.
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4.8. Endocochlear Potential
4.8.1. Round Window
Data were collected at the National institute on Deafness and Other Communication Disorders in Bethesda, MD. Methods for endocochlear potential (EP) measurement
from the round window have been described previously [83–85] Here, mice were anesthetized with 2,2,2-tribromoethanol (T4842, Sigma-Aldrich, St. Louis, MO, USA) at a dose
of 0.35 mg/g body weight. EP measurements were made using glass microelectrodes
inserted into the round window and through the basilar membrane of the first turn of the
cochlea. Induction of anoxia, allowing measurement of anoxic-state EP, was accomplished
by intramuscular injection of succinylcholine chloride (0.1 µg/g, NDC-0409-6629-02, Pfizer,
New York, NY, USA) after establishment of deep anesthesia followed by additional injection of 2,2,2-Tribromoethanol (T4842, Sigma-Aldrich, St. Louis, MO, USA). Anoxic-state EP
provides an indicator of passive sensory hair cell polarization. In the presence of functional
hair cells, the anoxic-state EP is negative, whereas the EP is zero if the hair cells are not
functional. Data were recorded digitally (Digidata 1440A and AxoScope 10; Molecular
Devices, San Jose, CA, USA) and analyzed using Clampfit10 (RRID: SCR_011323, Molecular Devices, San Jose, CA, USA). EP measurements were obtained from gonadectomized
female mice that received subcutaneous injections of vehicle (n = 6 mice) or E2 (n = 8 mice)
as described above with the examiner blinded to treatment received.
4.8.2. Lateral Wall
Data were collected at the Washington University School of Medicine in St Louis. Methods for EP measurement via the lateral wall were performed as previously described [86].
Briefly, animals underwent a single terminal EP measurement from the cochlear lower
basal turn of the left ear. Animals were anesthetized (60 mg/kg sodium pentobarbital,
IP) (Hospira Incorporated, Lake Forest, IL, USA) and positioned ventrally in a custom
headholder. Core temperature was maintained at 37.5 ± 1.0 ◦ C using a thermostatically
controlled heating pad in conjunction with a rectal probe (Yellow Springs Instruments
Model 73A) (YSI Incorporated, Yellow Springs, OH, USA). An incision was made along the
midline of the neck and soft tissues were blunt dissected and displaced laterally to expose
the trachea and left bulla. A tracheostomy was then made and the musculature over the
bulla was cut posteriorly to expose the bone overlying the round window. Using a fine
drill, a hole was made in the left cochlear capsule directly over scala media of the lower
basal turn using strial pigment as a guide. Glass capillary pipettes (20–40 MΩ) filled with
0.15 M KCl were mounted on a hydraulic microdrive (Frederick Haer, ME) and advanced
until a stable positive potential was observed that did not change with increased electrode
depth. The signal from the recording electrode was led to an AM Systems Model 1600
intracellular amplifier (A-M Systems, Sequim, WA, USA). A silver/silver chloride ball
inserted into the neck muscles served as ground.
4.9. Immunostaining
Immunostaining was performed as previously described [16] with minor modifications. Briefly, tissue was fixed by transcardial perfusion of 4% paraformaldehyde (PFA, Alfa
Aesar, Haverhill, MA, USA), followed by harvest of the temporal bones and further fixation
in 4% PFA at 4 ◦ C overnight. After adequate decalcification by incubation in 500 mM EDTA
(3–6 days), the cochlear ducts were dissected as described by the Eaton-Peabody Laboratories [87]. The tissue was permeabilized with PBS-0.3% Triton X-100 (Sigma-Aldrich,
St. Louis, MO, USA) and blocked in permeabilization buffer supplemented with 5% normal goat serum (Cell Signaling Technology, Danvers, MA, USA). Pre-synaptic ribbons
and post-synaptic densities were labelled using a monoclonal mouse anti-CtBP2 antibody
(1:200, BD Biosciences, San Jose, CA, USA) and a monoclonal mouse anti-GluR2 antibody
(1:2000, Sigma-Aldrich, St. Louis, MO, USA), respectively, followed by incubation with
the corresponding secondary antibodies, goat anti-mouse IgG2 Alexa Fluor® 488 and goat
anti-mouse IgG1 Alexa Fluor® 568 (1:1000, ThermoFisher Scientific, Waltham, MA, USA).
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Nuclei were counterstained with DAPI. The labelled tissue was mounted with the ProLong
Gold antifade reagent (ThermoFisher Scientific, Waltham, MA, USA).
4.10. Cochlear Frequency Mapping
Frequency mapping was performed as previously described [16]. Tissue was imaged
using a Nikon Eclipse E600 fluorescence microscope (Nikon, Tokyo, Japan) equipped with
an Infinity 3 camera (Lumenera, Ottawa, ON, Canada) and processing the images with the
Measure Line plugin for ImageJ (version 1.52A, National Institutes of Health, Bethesda, MD,
USA) developed by the Eaton-Peabody Laboratories, as described in [87] (https://www.
masseyeandear.org/research/otolaryngology/eaton-peabody-laboratories/histology-core,
accessed on 29 September 2020).
4.10.1. Synapse Counts
Stained tissues were imaged at the regions around 8 kHz, 16 kHz, 24 kHz, 32 kHz,
and 45 kHz using a Nikon W1 spinning disk confocal on a Nikon Ti2 inverted microscope
(Nikon, Japan) using a 60× oil objective and 0.2 µm sections. Paired synapses were
identified via the co-localization of GLUR2 and CTBP2. Synapses were counted on Z-stacks
using the ImageJ Cell Counter plugin.
4.10.2. Cytocochleograms
Outer hair cell nuclei counterstained with DAPI were imaged throughout the length
of the cochlea using a NikonEclipse E600 microscope (Nikon, Japan) equipped with an
Infinity 3 camera (Lumenera, Ottawa, Canada). The counts were expressed as percentage
of missing hair cells in 2 kHz intervals and binned within the following frequency intervals: 0.0–4.0 kHz, 4.0–5.6 kHz, 5.6–8.0 kHz, 8.0–11.3 kHz, 11.3–16.0 kHz, 16.0–22.6 kHz,
22.6–32.0 kHz, 32.0–45.2 kHz, 45.2–55.0 kHz.
4.11. In Situ Hybridization
Tissue for the fluorescent in situ hybridization assays was obtained from intact male
and female (n = 5 per sex) wildtype B6CBAF1/J mice (Jackson Laboratory, ME). At 10-weeks
of age, mice were euthanized via CO2 asphyxiation followed by decapitation. Immediately
following euthanasia, temporal bones were harvested from the head. The round and oval
windows of the cochlea were opened, and a small opening was made in the apex cochlea to
allow for increased perfusion during fixation. The temporal bones were fixed overnight at
4 ◦ C in freshly made RNase free 4% paraformaldehyde (Alfa Aesar, Haverhill, MA, USA) in
sterile 1× phosphate-buffered saline (Corning Inc., Corning NY, USA), then decalcified in
150 mM EDTA (Quality Biological, Gaithersburg, MD, USA) at 4 ◦ C for 3 days. Decalcified
ears were processed by a sucrose gradient and embedded in SCEM tissue embedding
medium (Section-Lab Co., Ltd., Hiroshima, Japan). Frozen tissue was cryosectioned at
12 µm thickness on a Leica CM 1850 cryostat microtome (Leica, Vienna, Austria).
The fluorescent in situ hybridization assay was performed as described in the RNAscope™
Multiplex Fluorescent v2 protocol (Advanced Cell Diagnostics, Newark, CA, USA), using the RNAscope™ Multiplex Fluorescent Reagent Kit v2 (Cat No. 323100) and three
RNAscope™ probes, ESR1 (Cat No. 478201-C3), ESR2 (Cat No. 316121-C2), and LYPD1
(Cat No. 318361). Images were taken at 40× magnification at the apical, middle, and basal
turns of the cochlea using a Nikon W1 spinning disk confocal microscope (University
of Maryland School of Medicine Center for Innovative Biomedical Resources [Confocal
Microscopy Facility]–Baltimore, MD, USA). Image processing was performed with the Fiji
ImageJ software to enhance signal clarity.
Quantification of Esr2 and Lypd1 co-expression was performed using the QuPath
software according to the methods described in the QuPath RNA ISH Analysis guide
(Advanced Cell Diagnostics, CA). Briefly, the spiral ganglion area was circled, and individual neurons were outlined using the ‘Cell detection’ program. Puncta for Esr2 were
identified using the ‘Subcellular detection’ feature and the detection parameters were
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adjusted to distinguish positive signals from the background. Co-expression was defined
by the number of Esr2 puncta overlapping with Lypd1 puncta.
4.12. Statistics
All statistical analyses were performed using Prism 8 software (GraphPad,
San Diego, CA, USA). Analyses of auditory thresholds were completed within groups using a repeated measure (RM) 2-way ANOVA (treatment × frequency) followed by Sidak’s
multiple comparison test, or between groups using a 2-way (treatment × frequency) or
3-way (treatment × frequency × biological sex) ANOVA followed by Tukey’s post-hoc
test. Within-group analyses of DPOAE thresholds were completed using a 2-way ANOVA
(treatment × frequency) followed by Sidak’s multiple comparison test. Analyses of wave-1
amplitudes were completed within groups at each frequency using a RM2-way ANOVA
(treatment × stimulus intensity) followed by Sidak’s multiple comparison test, or between
groups at each frequency using a 3-way ANOVA (treatment × stimulus intensity × noise
exposure) followed by Tukey’s post hoc test. Analyses of OHC loss and paired synapses
counts between groups were completed using a 2-way ANOVA (treatment × frequency)
followed by Sidak’s multiple comparison test. Analyses of endocochlear potentials and
RNAscope™ assays were completed using a student’s t-test. An adjusted p-value of <0.05
was set as the threshold for statistical significance for all pairwise comparisons. F-scores
for main effects of treatment and biological sex are provided in Table 1.
5. Conclusions
In conclusion, our data suggest that gonadal E2 protects against NIHL, and that this
E2 -conferred protection may be sex-dependent. E2 -replacement in gonadectomized adult
female mice reduces hearing loss following both a PTS-inducing and TTS-inducing noise
exposure. Histological analysis of cochlear tissue demonstrates that gonadectomy increases
susceptibility to, and E2 -replacement protects against, loss of OHC and the synaptic uncoupling of IHCs and SGNs following noise exposure. Furthermore, E2 -replacement in
gonadectomized female mice modulates the ABR and OHC physiology in the absence of
noise exposure, providing additional evidence of E2 ’s multi-modal modulatory capacity.
Taken together, our data present E2 signaling pathways as potential therapeutic targets to
mitigate noise-induced hearing loss.
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Table A1. F-scores for main effects of treatment and biological sex for the 2-way and 3-way ANOVAs.

Baseline Physiology
ABR Thresholds
Wave-1 Amplitudes
8 kHz
16 kHz
24 kHz
32 kHz

Main Effect

F-Score

p-Value

Treatment

28.53

<0.0001

Treatment
Treatment
Treatment
Treatment

57.07
39.34
43.79
32.35

<0.0001
<0.0001
<0.0001
<0.0001
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Table A1. F-scores for main effects of treatment and biological sex for the 2-way and 3-way ANOVAs.
Main Effect

F-Score

p-Value

Treatment

28.53

<0.0001

8 kHz

Treatment

57.07

<0.0001

16 kHz

Treatment

39.34

<0.0001

24 kHz

Treatment

43.79

<0.0001

32 kHz

Treatment

32.35

<0.0001

Vehicle Condition

Treatment

0.1903

0.6671

E2 Condition

Treatment

36.11

<0.0001

Treatment

0.7923

0.3903

Sex

0.1007

0.7516

Treatment

0.005573

0.9406

Sex

21.04

<0.0001

Treatment

17.15

<0.0001

Sex

27.25

<0.0001

Treatment

33.55

<0.0001

OHC Loss

Treatment

9.791

0.0019

Paired Synapses

Treatment

3.009

0.1033

Baseline

Treatment

2.144

0.1465

CTS

Treatment

34.03

<0.0001

TTS

Treatment

0.09137

0.7631

8 kHz

Treatment

30.99

<0.0001

16 kHz

Treatment

42.32

<0.0001

24 kHz

Treatment

59.31

<0.0001

32 kHz

Treatment

58.97

<0.0001

OHC Loss

Treatment

5.517

0.0278

Paired Synapses

Treatment

6.705

0.0100

Baseline Physiology
ABR Thresholds
Wave-1 Amplitudes

DPOAE Thresholds
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ABR Thresholds
Baseline
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